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Abstract 72 
Importance 73 
Associations between subclinical thyroid dysfunction and fractures are unclear and 74 
clinical trials are lacking. 75 
Objective 76 
To assess the association of subclinical thyroid dysfunction with hip, any, non-spine 77 
and spine fractures. 78 
Data Sources and Study Selection 79 
The databases of MEDLINE and EMBASE (inception to March 26, 2015) were 80 
searched without language restrictions for prospective cohort studies with thyroid 81 
function data and subsequent fractures. 82 
Data Extraction 83 
Individual participant data were obtained from 13 prospective cohorts in the United 84 
States, Europe, Australia and Japan. Euthyroidism was defined as thyrotropin (TSH) 85 
=0.45-4.49mIU/L, subclinical hyperthyroidism as TSH<0.45mIU/L and subclinical 86 
hypothyroidism as TSH≥4.50-19.99mIU/L with normal thyroxine concentrations. 87 
Main Outcome Measures 88 
The primary outcome was hip fracture. Any fracture, non-spine fracture, and clinical 89 
spine fractures were secondary outcomes. 90 
Results 91 
Among 70,298 participants, 4092 (5.8%) had subclinical hypothyroidism and 2219 92 
(3.2%) had subclinical hyperthyroidism. During 762,401 person-years of follow-up, hip 93 
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fracture occurred in 2975 participants (4.6%; 12 studies), any fracture in 2528 (9.0%; 8 94 
studies), non-spine fracture in 2018 (8.4%; 8 studies) and spine fracture in 296 (1.3%; 95 
6 studies). In age- and sex-adjusted analyses, the hazard ratios (HR) for subclinical 96 
hyperthyroidism vs. euthyroidism were 1.36 (95% confidence interval 1.13-1.64; 146 97 
events in 2082 participants vs. 2534/56,471) for hip fracture, 1.28 (1.06-1.53; 121/888 98 
vs. 2203/25,901) for any fracture, 1.16 (0.95-1.41; 107/946 vs. 1745/21,722) for non-99 
spine fracture and 1.51 (0.93-2.45; 17/732 vs. 255/20,328) for spine fracture. Lower 100 
TSH was associated with higher fracture rates, with HR for TSH<0.10mIU/L of 1.61 101 
(1.21-2.15; 47/510 participants) for hip, 1.98 (1.41-2.78; 44/212) for any, 1.61 (0.96-102 
2.71; 32/185) for non-spine and 3.57 (1.88-6.78; 8/162) for spine fracture. Risks were 103 
similar after adjustment for other fracture risk factors. Endogenous subclinical 104 
hyperthyroidism (excluding thyroid medication users) was associated with HRs of 1.52 105 
(1.19-1.93) for hip, 1.42 (1.16-1.74) for any, and 1.74 (1.01-2.99) for spine fractures. 106 
No association was found between subclinical hypothyroidism and fracture risk. 107 
Conclusions and Relevance 108 
Subclinical hyperthyroidism was associated with an increased risk of hip and other 109 
fractures, particularly among those with TSH<0.10mIU/L and those with endogenous 110 
subclinical hyperthyroidism. Further study is needed to determine whether treating 111 
subclinical hyperthyroidism can prevent fractures. 112 
Abstract Word count 113 
350 words. 114 
Keywords 115 
Subclinical Thyroid Dysfunction, Fractures, Hip, Prospective Studies, Cohort Studies116 
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Introduction 117 
Overt hyperthyroidism is an established risk factor for osteoporosis and fractures1. 118 
More subtle alterations in thyroid function found in subclinical thyroid dysfunction, 119 
defined as abnormal TSH with normal free thyroxine, could also be associated with 120 
increased fracture risk and bone loss2-4. 121 
Data on the association between subclinical thyroid dysfunction and fracture risk are 122 
conflicting in prospective cohort studies, due to inclusion of participants with overt 123 
thyroid disease3,5 and small sample sizes of participants with thyroid dysfunction6,7 or 124 
fracture events8. To our knowledge, no clinical trial has examined the effect of treating 125 
subclinical thyroid dysfunction on fracture risks. A recent study-level meta-analysis of 126 
prospective cohorts found an increased fracture risk in subclinical hyperthyroidism, but 127 
interpretation was limited by population heterogeneity, discrepant definitions of 128 
fractures and different TSH cut-offs to define subclinical thyroid dysfunction9, which 129 
could not be addressed in a study-level meta-analysis. 130 
For these reasons, we performed a pooled analysis of individual participant data of 131 
multiple large cohorts that assessed the association of subclinical thyroid dysfunction 132 
with risk for hip fractures, as well as non-spine, clinical spine, and fractures of any 133 
location. This approach allows exploration of the relationship of age, gender, and TSH 134 
levels with the association of subclinical thyroid dysfunction and fractures, and is 135 
considered an optimal approach for combining evidence10.  136 
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Methods 137 
This individual participant data analysis was performed according to a predefined 138 
protocol11. 139 
Study selection 140 
We performed a systematic literature search in MEDLINE and EMBASE, from inception 141 
to March 26, 2015, without language restriction, for prospective cohorts of adults with 142 
baseline TSH and free T4 (FT4) levels12 and follow up for incident fractures. We 143 
excluded studies that included only participants with overt thyroid dysfunction or 144 
individuals taking thyroid-altering medications (thyroxine, iodine, oral corticosteroids, 145 
amiodarone, anti-thyroid drugs). We conducted the search on an Ovid (MEDLINE) 146 
server using broadly defined Medical Subject Headings: thyroid diseases, 147 
hypothyroidism, hyperthyroidism, thyroid hormones, thyrotropin, subclinical 148 
hyperthyroidism, subclinical hypothyroidism, subclinical dysthyroidism or subclinical 149 
thyroid and fractures or osteoporosis. We used a filter to extract prospective studies 150 
(MEDLINE cohort-study filter)13, but without year limitation. The search was also 151 
conducted in EMBASE using similar terms. We searched bibliographies of key articles 152 
in the field. Two authors (M.R.B and C.D.W) independently screened the abstracts of 153 
the search results, and independently assessed the remaining full-text articles for 154 
eligibility. Any disagreement was resolved through the help of a third author (D.C.B)9. 155 
We also asked cohorts of the Thyroid Studies Collaboration12,14-16 for unpublished 156 
prospective fracture data. 157 
All qualifying cohorts were invited to join and provide individual participant data on 158 
baseline thyroid function, participant characteristics, bone metabolism-altering and 159 
thyroid medications and fracture data. We conducted this individual participant data 160 
analysis in collaboration with investigators from each cohort to resolve data issues17. 161 
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Individual cohort results were validated against published results. Four cohorts that had 162 
not previously published fracture data18-21 provided exact procedures for data collection 163 
and adjudication of fracture data. For comparability with other cohorts in the present 164 
analysis, we used the random sample of the “Osteoporotic Fractures in Men (MrOS) 165 
Study”7 from 5994 participants at the baseline visit9. 166 
Definition of subclinical thyroid dysfunction 167 
We used a uniform TSH threshold to maximize comparability, based on previously 168 
established thresholds12. Euthyroidism was defined as TSH 0.45-4.49 mIU/L. 169 
Subclinical hyperthyroidism was defined as TSH <0.45 mIU/L with normal FT4 levels, 170 
and was further stratified as suppressed TSH (<0.10 mIU/L), and low but not 171 
suppressed TSH (0.10-0.44 mIU/L). Subclinical hypothyroidism was defined as TSH 172 
4.5-19.99 mIU/L with normal FT4 levels. Participants with a missing FT4 level and a 173 
TSH level within the range for subclinical thyroid dysfunction (1024 participants) were 174 
considered as having subclinical thyroid dysfunction, because most adults with TSH 175 
levels in this range have subclinical and not overt thyroid dysfunction (eTable 1)22. 176 
Cohorts using first-generation TSH assays were excluded from analyses of subclinical 177 
hyperthyroidism, because of insufficient sensitivity of first generation thyroid assays23. 178 
Due to greater inter-method variation, we used cohort-specific cut-offs for FT4 and T3 179 
levels (eTable 1). We performed a sensitivity analysis on persistent thyroid dysfunction 180 
using repeated TSH and FT4 measurements (available in 5 cohorts, follow-up duration 181 
in eTable 5). We performed additional sensitivity analyses excluding participants using 182 
thyroid-altering medications to estimate the risk associated with endogenous 183 
subclinical thyroid dysfunction, and excluding participants with missing FT4 levels, or 184 
abnormal total or free T3 levels (measured in 4 out of 13 cohorts). 185 
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Outcomes 186 
Our a priori defined primary outcome was incident hip fracture. Secondary outcomes 187 
were incident fractures of any location, non-spine, and clinical spine fractures. We 188 
standardized outcome definitions (eTable 1). Incident hip fractures typically included 189 
fractures of femoral neck, pertrochanteric, and subtrochanteric fractures, excluding 190 
pathologic and peri-prosthetic fractures. Incident non-spine fractures were defined as 191 
hip or any other non-pathologic fracture excluding the spine, and excluding fractures of 192 
skull/face, ankle, finger, and toe, which are not typically affected by increased bone 193 
fragility. Incident spine fractures were defined as clinically diagnosed and 194 
radiographically confirmed thoracic and lumbar spine fractures, excluding cervical and 195 
sacral fractures as these usually occur due to high-energy trauma that is unrelated to 196 
bone fragility. We restricted our spine fracture outcome to those that were clinically 197 
diagnosed and did not consider spine fractures identified only by scheduled 198 
radiographs, to focus analyses on associations with outcomes that are more likely to be 199 
symptomatic24, and therefore of greater clinical relevance to patients25. The outcome of 200 
any fracture was defined as the first event of either non-spine or clinically diagnosed 201 
spine fracture. Cohorts with fracture data only for parts of the skeleton, such one study 202 
with hip fracture data only8, were not included for this outcome. 203 
In a secondary analysis, we compared fracture risk between thyroxine-treated and 204 
untreated participants at baseline, irrespective of thyroid function test results, to assess 205 
fracture risk associated with thyroxine use. 206 
To evaluate study quality, we used the individual criteria of the Newcastle-Ottawa 207 
Quality Assessment Scale26 (eTable 2, eMethods). We performed sensitivity analyses 208 
excluding cohorts that did not meet different individual criteria of this scale. 209 
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Statistical analyses 210 
We used established methods 10,17 with a two-step approach, first analyzing the 211 
association of subclinical thyroid dysfunction with outcomes using separate Cox 212 
proportional hazard models for each cohort (Stata 12.1, StataCorp, College Station, 213 
TX, USA), and in a second step calculating pooled estimates using random-effects 214 
models27. Time to event was calculated for each outcome from baseline to first event. 215 
For cohorts with no event in some subgroups of thyroid function, penalized maximum 216 
likelihood estimation models28 were used to derive hazard ratios (HR) and 95% 217 
confidence intervals (CI) (SAS 9.3, SAS Institute Inc., Cary, NC, USA). Strata with less 218 
than six participants per cohort were excluded from pooling due to unreliable estimates. 219 
We summarized results using forest plots (Review Manager 5.3.3, Nordic Cochrane 220 
Centre, Copenhagen, Denmark). We calculated the variance estimate τ2 (tau-squared) 221 
as a measure of heterogeneity in estimates across cohorts. A τ2 ≤0.04 was pre-222 
specified to represent low, >0.04–0.36 moderate, and ≥0.36 high heterogeneity29. P 223 
values <0.05 were regarded as significant, and testing was two-sided. 224 
Primary analyses were adjusted for age and gender, and then for other known risk 225 
factors for fractures, as some might be potential mediators (e.g. BMI) of the association 226 
between subclinical thyroid dysfunction and fractures. Based on a literature search of 227 
potential confounders for this association, taking into account their prevalence and 228 
strength of their association with fractures and possible influence on thyroid function, 229 
we further adjusted for BMI30 and smoking status31, which were available in all cohorts. 230 
In sensitivity analyses, we also (1) adjusted for diabetes mellitus32, (2) excluded 231 
participants on thyroid-altering medication (oral corticosteroids, amiodarone, iodine), 232 
(3) excluded participants on anti-fracture medication (bisphosphonates, calcitonin, 233 
selective estrogen receptor modulator, parathyroid hormone), (4) limited the analysis to 234 
the eight studies with formal adjudication or those with the most uniform fracture 235 
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definition, (5) restricted the analysis to participants with repeated thyroid function 236 
measurement to assess the association with persistent thyroid dysfunction, (6) 237 
excluded cohorts with loss to follow-up rates >5% and/or fracture ascertainment 238 
methods other than independent blind assessment or record linkage (eTable 2), (7) 239 
excluded participants with missing FT4 levels or abnormal free/total T3, (8) excluded 240 
studies inconsistent with the proportional hazard assumption, (9) excluded studies 241 
because of potential publication bias in funnel plots, and (10) applied age-specific TSH 242 
reference ranges33. 243 
To explore potential sources of heterogeneity, we performed pre-defined subgroup 244 
analyses according to age, gender and TSH levels. We calculated linear p for trend 245 
and p for interaction for stratified analyses. We used Poisson models to calculate event 246 
rates34. The proportional hazard assumption was assessed by graphical methods (log-247 
log graphs) and the Schoenfeld test35. We excluded cohorts violating the proportional 248 
hazard assumption in sensitivity analyses. We visually assessed funnel plots of age- 249 
and gender-adjusted estimates and used the Egger test to assess for publication 250 
bias36.  251 
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Results 252 
Among 1371 studies identified in our literature search, 13 prospective cohorts met 253 
inclusion criteria (eFigure 1). The final sample consisted of 70,298 participants (median 254 
age 64 years, 61.3% women), a median follow-up of 12.1 years, and a total follow-up of 255 
762,401 person-years (Table 1). 63,987 (91.0%) of the participants were euthyroid, 256 
4092 (5.8%) had subclinical hypothyroidism, and 2219 (3.2%) had subclinical 257 
hyperthyroidism, including 1669 (2.4%) with low but not suppressed TSH (0.10-0.44 258 
mIU/L) and 550 (0.8%) with suppressed TSH (<0.10 mIU/L). We excluded the 259 
Nagasaki Adult Health Study20 from the analysis of subclinical hyperthyroidism 260 
because it used the first-generation thyrotropin assays. 261 
Incident hip fractures were collected in all cohorts except one18, resulting in a study 262 
sample of 64,691 participants for the primary outcome. Data were available for any 263 
fracture in 28,561 participants from eight cohorts, for non-spine fractures in 24,155 264 
participants from eight studies, and for clinical spine fractures in 22,491 participants 265 
from six cohorts. During follow-up, 2975 (4.6% in 12 studies) participants had an 266 
incident hip fracture, 2528 (9.0% in eight studies) a fracture in any location, 2018 (8.4% 267 
in eight studies) a non-spine fracture and 296 (1.3% in six studies) a spine fracture. 268 
Study quality was good (eTable 2). Two cohorts had a loss to follow-up >5% and two 269 
cohorts did not ascertain fractures with independent blind assessment or record 270 
linkage. Five cohorts did not formally adjudicate fractures. 271 
Subclinical hyperthyroidism and fracture risk 272 
In age- and sex-adjusted analyses, compared to euthyroidism, subclinical 273 
hyperthyroidism was associated with hazard ratios of 1.36 (95% confidence interval 274 
(95%CI) 1.13-1.64; 6.0 vs. 4.9/1000 person-years, respectively) for hip fracture, 1.28 275 
(1.06-1.53; 14.4 vs. 11.2/1000 person-years) for any fracture, 1.16 (0.95-1.41; 9.9 vs. 276 
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8.1/1000 person-years) for non-spine fracture, and 1.51 (0.93-2.45; 1.8 vs. 1.2/1000 277 
person-years) for spine fracture (Figure 1). Numbers of fracture events and 278 
participants, as well as individual hazard ratios with confidence intervals for each 279 
cohort are described in Figure 1. Two individual studies found that subclinical 280 
hyperthyroidism was associated with increased risk for hip fractures (Cardiovascular 281 
Health Study and the Sheffield study). No individual study found a statistically 282 
significant association of subclinical hyperthyroidism with any, non-spine or clinical 283 
spine fracture. Although confidence intervals were large in some cohorts, heterogeneity 284 
was low for all outcomes (all τ2 ≤0.01). 285 
Figure 2 displays stratified analyses for incident hip, any, non-spine, and spine fracture 286 
events comparing subclinical hyperthyroidism vs. euthyroidism. Men with subclinical 287 
hyperthyroidism had higher HRs than women for all fracture outcomes, without 288 
statistically significant interactions except for spine fractures (p for interaction ≤ 0.02). 289 
Risks did not differ when stratified by age. Figure 3 displays the association between 290 
subclinical hyperthyroidism and the risk of fracture by TSH category. Risks for hip, any, 291 
and spine fracture were higher in participants with lower TSH levels. TSH levels < 292 
0.10mIU/L were not associated with increased risk of non-spine fracture. The 293 
multivariable analysis yielded similar results (eTable 3). 294 
Sensitivity analyses excluding participants with missing FT4, T3 or those on anti-295 
osteoporotic medication, restricting the analysis to studies with formal adjudication, 296 
those with the most uniform fracture definition, or excluding studies inconsistent with 297 
the proportional hazard assumption (possible publication bias in funnel plots), with >5% 298 
loss to follow-up, with fracture ascertainment methods other than independent blind 299 
assessment or record linkage all yielded similar results (eTables 4-6). After excluding 300 
participants who used thyroid or anti-thyroid medication at baseline (4%), participants 301 
with endogenous subclinical hyperthyroidism had statistically significant increased risk 302 
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estimates for all fracture outcomes except for non-spine fractures. Although point 303 
estimates were similar for persistent thyroid dysfunction, our findings were non-304 
statistically significant with larger confidence intervals, likely due to dataavailable only 305 
in five cohorts (n=25,497 participants, eTable 5). Restricting the analysis to nine 306 
cohorts with previously published fracture data generally yielded similar risk estimates 307 
(eTable 6), without statistically significant interactions compared to four cohorts with 308 
unpublished fracture data. When restricting analyses to four cohorts with unpublished 309 
fracture data, results were non-statistically significant. 310 
Subclinical hypothyroidism and fracture risk 311 
We found no association between subclinical hypothyroidism and fracture risks either 312 
overall (eFigure 2) or in stratified analyses (eTable 7), with a HR compared to euthyroid 313 
participants of 0.96 (95%CI 0.83-1.10) for hip fracture, 1.02 (0.89-1.18) for any fracture, 314 
1.06 (0.90-1.24) for non-spine fracture and 0.96 (0.59-1.55) for spine fracture. 315 
Sensitivity analyses did not change results (eTable 8). 316 
Treatment with thyroxine and fracture risk 317 
When comparing participants treated with thyroxine at baseline to untreated 318 
participants regardless of thyroid function, treatment with thyroxine was not associated 319 
with any of the fracture outcomes (eTable 9).  320 
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Discussion 321 
In this analysis of 70,298 individual participants from 13 prospective cohorts, subclinical 322 
hyperthyroidism was associated with an increased risk for hip and other fractures, with 323 
the highest risks in individuals with suppressed TSH <0.10 mIU/L and those with 324 
endogenous subclinical hyperthyroidism. Conversely, our study found no association 325 
between subclinical hypothyroidism and fractures. Our pooled data analysis 326 
demonstrates that subclinical hyperthyroidism is associated with increased fracture risk 327 
and provides insight on defined sub-groups. 328 
No pooled individual participant data analysis has previously assessed the association 329 
of subclinical thyroid dysfunction and fracture events. The Cardiovascular Health Study 330 
prospectively followed a cohort of 3567 older adults and found that subclinical 331 
hyperthyroidism and hypothyroidism were associated with increased hip fracture risk in 332 
men, with HRs 3.07 (95%CI 1.11-8.46) and 1.86 (95%CI 1.09-3.16), respectively8. Our 333 
results confirm the association of subclinical hyperthyroidism with hip fracture risk. A 334 
prospective case-cohort study of 686 women aged over 65 years found an odds ratio of 335 
4.5 (95%CI 1.3-15.6) for spine fracture detected in serial radiographs in women with 336 
TSH ≤0.10 mIU/L compared with normal TSH levels after a mean follow-up of 3.7 337 
years3. Our study also found that endogenous subclinical hyperthyroidism was 338 
associated with increased risk of clinically diagnosed spine fractures (HR 1.74, 95%CI 339 
1.01-2.99).  However, since not all radiographic fractures are clinically diagnosed37, it is 340 
difficult to directly compare results with the prior study. Although there is some 341 
evidence that thyroid hormone is associated more strongly with changes in cortical 342 
than in trabecular bone38,39, we did not observe a stronger association with a more 343 
cortical (hip) vs. more trabecular (spine) fracture site. 344 
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Thyroid function may influence fracture risk through several mechanisms. First, thyroid 345 
hormones have been shown to have effects on osteoclasts and osteoblasts, with 346 
thyroid status in the upper normal range or excess thyroid hormones leading to 347 
accelerated bone turnover with bone loss and increased fracture risk4. Second, the 348 
association of subclinical hyperthyroidism with increased fracture risk might be 349 
mediated by an increased risk of falls40 through effects on muscle strength and 350 
coordination41,42. Third, the increase in fracture risk could be related to thyroxine 351 
supplementation. In the TEARS study, participants on thyroid hormone replacement 352 
had a higher rate of fractures when TSH was suppressed compared with treated 353 
euthyroid participants (adjusted HR 2.02; 95%CI 1.55-2.62). However, participants with 354 
overt thyroid dysfunction might have been included in the TEARS Study. FT4 levels 355 
were not measured and the study did not include an untreated control group5. Another 356 
nested case-control study of >120,000 prevalent levothyroxine users showed that 357 
levothyroxine use was associated with  increased fracture risk compared to 358 
discontinuation of levothyroxine more than six months previously.  However, TSH 359 
levels were not considered in these analyses43. Our results showed an association of 360 
subclinical hyperthyroidism with increased risk of all fracture outcomes except non-361 
spine fractures, when thyroid medication users (thyroxine and anti-thyroid medication) 362 
were excluded from analyses. These results suggest that endogenous hyperthyroidism 363 
is associated with increased fracture risk. Endogenous subclinical hyperthyroidism may 364 
be undetected for years because symptoms of subclinical hyperthyroidism are often 365 
non-specific or absent. This phenomenon has the potential to lead to a greater length 366 
of time for adverse associations with bone metabolism. Baseline thyroxine use was not 367 
associated with increased fracture risk when TSH levels were not taken into account. A 368 
possible explanation for this is that patients on replacement therapy have more 369 
frequent thyroid function tests followed by thyroxine dosage change when 370 
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overtreatment is detected, and thus do not exhibit a long-standing form of subclinical 371 
hyperthyroidism.  372 
Our study has important strengths. First, to our knowledge this is the largest study of 373 
adults with subclinical thyroid dysfunction and prospective follow-up of fracture 374 
outcomes. An individual participant data analysis is not subject to potential aggregation 375 
bias arising in study-level meta-analyses44 and is therefore seen as the optimal 376 
approach to combining evidence across multiple studies and performing time-to-event 377 
analyses45. In addition, individual participant data analysis enables use of standardized 378 
definitions of predictors and outcomes, and standardized adjustment for confounding 379 
factors10, thus producing more robust results. We were also able to include four cohort 380 
studies that have not previously published their data on thyroid dysfunction and 381 
fractures (Busselton Health Study19, PROSPER Study18, InCHIANTI Study21 and 382 
Nagasaki Adult Health Study20), and all prospective cohorts identified through our 383 
systematic search agreed to participate, which increased our power to detect potential 384 
associations.  385 
Our study has limitations. First, in the majority of cohorts, thyroid function was 386 
assessed at baseline only, which is a limitation of most published large cohorts on the 387 
risk of subclinical thyroid dysfunction12,46. Subclinical hypothyroidism has an annual 388 
rate of 2-6% for spontaneous progression to overt thyroid dysfunction47, while 15 to 389 
65% revert to normal thyroid function over follow-up periods of one to six years48. 390 
Subclinical hyperthyroidism similarly progresses to overt disease in 1-2% of affected 391 
individuals per year49,50. In our pooled data, 5.3% of participants with baseline 392 
subclinical hyperthyroidism developed overt hyperthyroidism on follow-up thyroid 393 
function assessment, and 1.6% of participants when excluding thyroxine use at 394 
baseline (endogenous form). A sensitivity analysis restricted to participants with 395 
persistent subclinical thyroid dysfunction using repeated thyroid function measurement 396 
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in five cohorts with available data yielded similar HRs for hip and any fracture 397 
outcomes, with non-statistically significant results, possibly due to smaller sample 398 
sizes. Second, it was not possible to achieve a uniform definition for each fracture type 399 
across all cohorts. Sensitivity analyses limited to cohorts with the most uniform fracture 400 
definition, however, yielded similar results. Third, we defined subclinical 401 
hyperthyroidism by low TSH and normal FT4 levels, as T3 levels were measured only 402 
in four cohorts. Consequently, participants with T3 toxicosis may have been defined as 403 
having subclinical hyperthyroidism, but results remained similar in sensitivity analyses 404 
excluding participants with abnormal T3 levels in the cohorts that had this 405 
measurement available. Likewise, we may have included participants with non-406 
thyroidal illness from other cohorts in which T3 levels were not measured. Fourth, only 407 
eight of 13 studies formally adjudicated fracture outcomes; sensitivity analyses limited 408 
to these studies yielded similar results. Fifth, our pooled data contained relatively few 409 
young adults and a primarily white population, thus limiting generalizability. Sixth, in 410 
spite of the large number of participants, event numbers were low for some outcomes, 411 
such as clinical spine fractures, limiting power for sub-group analyses. Seventh, 412 
younger participants may have been more likely to experience traumatic fractures and 413 
mechanism of injury was not collected in most cohorts. However, fractures in locations 414 
not typically associated with osteoporosis/low bone mass density were excluded. 415 
Eighth, history of fracture or history of maternal/parental hip fracture were unavailable 416 
for most participants and we could not rule out the possibility of residual confounding. 417 
Current guidelines recommend that treatment of subclinical hyperthyroidism should be 418 
strongly considered if TSH is persistently <0.1 mIU/L in all individuals ≥65 years old, 419 
and that treatment should also be considered if TSH is low but ≥0.1 mIU/L in 420 
individuals ≥65 years old51. Our results from pooling data of all available prospective 421 
cohorts, showing increased fracture risk in subclinical hyperthyroidism with even higher 422 
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risk for participants with TSH <0.10 mIU/L, are consistent with these recommendations. 423 
Due to the above-mentioned limitations, evidence from observational data should be 424 
used with caution in clinical decision-making. Some small randomized controlled trials 425 
(RCT) (N=14-66) have studied the short-term effect (follow-up time of 6–14 months) of 426 
subclinical thyroid dysfunction treatment on bone mineral density with conflicting 427 
results52-55, but no RCT has been conducted on treating subclinical thyroid dysfunction 428 
to reduce fracture risk. There are also no studies comparing the relative benefit of 429 
treatment of subclinical hyperthyroidism vs. treatment with bisphosphonates or other 430 
anti-fracture agents. 431 
Conclusions 432 
Subclinical hyperthyroidism was associated with an increased risk of hip and other 433 
fractures, particularly among those with TSH <0.10mIU/L and those with endogenous 434 
subclinical hyperthyroidism. Further study is needed to determine whether treating 435 
subclinical hyperthyroidism can prevent fractures.  436 
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Figure 1. Forest plots of the association between subclinical hyperthyroidism and the risk of 742 
fractures 743 
Hip, non-spine, spine and any fractures in subclinical hyperthyroidism vs. euthyroidism. Age and sex-adjusted 744 
hazard ratios (HR) and their 95% confidence intervals (CI) are represented by squares or diamonds. The sizes of the 745 
squares are proportional to the inverse of the variance of the HR. Not every outcome was available for each study. 746 
τ2 measures heterogeneity in effect estimates across cohorts, with a pre-specified τ2 of ≤0.04 representing low 747 
heterogeneity and >0.04 to <0.36 representing moderate heterogeneity. Abbreviations: EPIC: European Prospective 748 
Investigation of Cancer. HUNT: Nord-Trøndelag Health Study. 749 
  750 
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Figure 2. Stratified analyses for the association between subclinical hyperthyroidism and the risk of 751 
fractures 752 
Abbreviations: CI, confidence interval; HR, hazard ratio; TSH, thyroid-stimulating hormone 753 
a The PROSPER study was not included because follow-up data were only available for any fracture 754 
b The HUNT, Cardiovascular Health Study, Sheffield and OPUS  studies were not included because follow-up data for 755 
any fracture were not available.  756 
c The HUNT, Cardiovascular Health Study, Leiden 85-plus and PROSPER studies were not included because follow-up 757 
data for non-spine fractures were not available.  758 
d The HUNT, Cardiovascular Health Study, Leiden 85-plus, Sheffield, OPUS and PROSPER studies were not included 759 
because follow-up data for spine fractures were not available.  760 
e These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata. 761 
All HRs were age and sex-adjusted. The multivariable analysis yielded similar results (eTable 3).  762 
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Figure 3. Association between subclinical hyperthyroidism and the risk of fracture by TSH 763 
category 764 
Abbreviations: CI, confidence interval; HR, hazard ratio; TSH, thyroid-stimulating hormone 765 
a The PROSPER study was not included because follow-up data were only available for any fracture 766 
b The HUNT, Cardiovascular Health Study, Sheffield and OPUS  studies were not included because follow-up data for 767 
any fracture were not available.  768 
c The HUNT, Cardiovascular Health Study, Leiden 85-plus and PROSPER studies were not included because follow-up 769 
data for non-spine fractures were not available.  770 
d The HUNT, Cardiovascular Health Study, Leiden 85-plus, Sheffield, OPUS and PROSPER studies were not included 771 
because follow-up data for spine fractures were not available.  772 
All HRs were age and sex-adjusted. The multivariable analysis yielded similar results (eTable 3). 773 
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Table 1. Baseline characteristics of individuals in included studies (n = 70,298) 
Study Description of Study Sample 
No. of 
Particip
ants 
Age 
Median 
(Range), y a 
Women 
No. (%) 
Thyroid Medication 
Users, No. (%) c Follow-up d 
Subclinical 
Hypothyroidism 
b 
Subclinical 
Hyperthyroidism 
b 
At 
Baseline 
During 
Follow-Up Start, y 
Duration, 
Median (IQR), y 
Person-
Years 
United States           
Cardiovascular Health Study8 CDAs with Medicare eligibility in 4 US communities 3555 71 (65-100) 2185 (61.5) 543 (15.3) 159 (4.5) 295 (8.3) 629 (17.7) 1989-1990 12.8 (7.5-18.8) 45,160 
Health ABC Study56 CDAs aged 70-79y with Medicare eligibility in 2 US communities 2764 74 (69-81) 1407 (50.9) 335 (12.1) 82 (3.0) 267 (9.7) 383 (13.9) 1997 12.8 (8.1-13.2) 29,292 
Osteoporotic Fractures in Men (MrOS)7 CDMs aged 65+ in 6 US clinical centers 1588 73 (65-99) 0 (0.0) 147 (9.3) 30 (1.9) 121 (7.6) 152 (9.6) 2000-2002 11.1 (8.0-11.8) 15,133 
Europe                       
EPIC-Norfolk Study46 Adults aged 45-79 y living in Norfolk, England 13,066 58 (40-78) 7104 (54.4) 720 (5.5) 360 (2.8) 439 (3.4) NA 1995-1998 12.4 (11.6-13.3) 155,661 
HUNT Study57, e Adults living in Nord-Trøndelag County, Norway 33,646 57 (19-99) 22,988 (68.3) 1313 (3.9) 945 (2.8) 1576 (4.7) NA 1995-1997 12.2 (11.6-12.8) 369,413 
Invecchiare in Chianti Study (InCHIANTI)21 CDAs aged 65y+ living in Tuscany, Italy 1186 71 (21-102) 664 (56.0) 33 (2.8) 87 (7.3) 28 (2.4) 48 (4.0) 1998 9.1 (7.2-9.3) 9393 
Leiden 85-plus Study58 All adults aged 85y living in Leiden, the Netherlands 514 85 (85-85) 336 (65.4) 35 (6.8) 23 (4.5) 17 (3.3) 29 (5.6) 1997-1999 4.9 (2.2-8.2) 2736 
Osteoporosis and Ultrasound Study (OPUS)41, f Women aged 20-80y living in Germany, France, UK 1433 63 (20-80) 1433 (100.0) 12 (0.8) 216 (15.1) 0 (0.0) NA 1999-2001 6.0 (5.8-6.3) 8556 
PROSPER Study18 
Older community-dwelling adults at high 
cardiovascular risk in the Netherlands, 
Ireland and Scotland 
5563 75 (69-83) 2824 (50.8) 306 (5.5) 133 (2.4) 184 (3.3) 252 (4.5) 1997-1999 3.2 (3.0-3.5) 17162 
Rotterdam Study59 Adults aged 55y+ living in Rotterdam, the Netherlands 1838 69 (55-93) 1127 (61.3) 107 (5.8) 120 (6.5) 42 (2.3) NA 1989-1992 15.2 (10.2-16.2) 24,031 
Sheffield Study6 Women aged 50-85y living in Sheffield, UK 334 63 (50-86) 334 (100.0) 32 (9.6) 11 (3.3) 5 (1.5) 21 (6.3) 1990-1991 10.0 (5.3-10.1) 2597 
Australia                       
Busselton Health Study19 Adults living in Busselton, Western Australia 2049 51 (18-90) 1006 (49.1) 89 (4.3) 53 (2.6) 19 (0.9) 34 (1.7) 1981 20.0 (17.2-20.0) 35,607 
Asia       
Nagasaki Adult Health Study20 Atomic bomb survivors in Nagasaki, Japan 2762 57 (38-92) 1686 (61.0) 420 (15.2) NA g 39 (1.4) 6 (0.2) 1984-1987 20.2 (10.0-25.9) 47,660 
Overall 13 Cohorts 70,298 64 (18-102) 43,094 (61.3) 4092 (5.8) 2219 (3.2) 3032 (4.3) 1554 (9.0) 1981-2002 12.1 (8.3-13.0) 762,401 
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 75 
Abbreviations: CDA, community-dwelling adults; CDM, community-dwelling men; EPIC, European Prospective Investigation of Cancer; Health ABC Study, Health Aging and Body Composition 76 
Study; HUNT, Nord-Trøndelag Health Study; IQR, inter-quartile range (25th-75th percentiles); NA, not available; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; y, years  77 
a Participants younger than 18 years old were excluded.      78 
b We used a common definition of subclinical thyroid dysfunction, whereas TSH cutoff values varied among the previous reports from different cohorts, resulting in different numbers from previous 79 
reports.      80 
c Data on baseline thyroid medication use (thyroxine, antithyroid drugs) were unavailable for 273 participants of the HUNT study, 1 participant of the Cardiovascular Health Study, 64 participants of 81 
the Osteoporotic Fractures in Men (MrOS) study, 8 participants of the Health ABC study and 1 participant of the Rotterdam study. Data on thyroid medication use during follow-up were unavailable 82 
for 294 participants of the Osteoporotic Fractures in Men (MrOS) study, 119 participants of the Invecchiare in Chianti study, 2509 participants of the Nagasaki Adult Health Study, 56 participants of 83 
the Sheffield Study, and for all participants of the HUNT study, EPIC-Norfolk study, Rotterdam study and Osteoporosis and Ultrasound Study.      84 
d For all cohorts, we used the maximum follow-up data available (calculated as time to first hip or any fracture or censor date/death), which might differ from previous reports for some cohorts. 85 
e The sample included for the original article of the HUNT study used several inclusion/exclusion criteria that differed from those used here (such as excluding participants younger than 40 years, 86 
those with previous fractures or previous thyroid disease), resulting in different numbers of participants.  87 
f The original Osteoporosis and Ultrasound Study (OPUS) was a population-based study with no exclusions. The sample included here is the thyroid hormone sub-study of OPUS, which excluded 88 
thyroid medication users.  89 
g 21 participants with TSH < 0.45mIU/L and free thyroxine within the normal range were excluded from the Nagasaki cohort due to the use of a first-generation TSH assay that is not sensitive 90 
enough to detect subclinical hyperthyroidism 91 
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eMethods: Study Quality Assessment 24 
The Newcastle-Ottawa Quality Assessment Scale1 items assessed were: 1-2) representativeness of the 25 
exposed/unexposed cohort (population-based vs. convenience-based), 3) ascertainment of exposure 26 
(thyroid function measurement), 4) availability of relevant confounders for adjustment, 5) assessment of 27 
outcome with objective fracture assessment (defined as using radiographic images and/or reviewing 28 
radiologists or orthopedic reports and other support documents to verify clinical diagnoses; or record 29 
linkage on database records) and formal adjudication procedure (defined as using predefined criteria 30 
applied by experts), 6) length of follow-up period, and 7) loss to follow-up. We did not list the presence 31 
of outcome (current fracture) at cohort study start, as we excluded participants with acute fracture at 32 
baseline from the analysis. Study quality was assessed independently by two authors (M.R.B and T.H.C.). 33 
eTable 1: Definitions of Subclinical Thyroid Dysfunction and Fracture Events 
Study Subclinical hypothyroidism Subclinical hyperthyroidism Event definition
g 
Hip fracture Any fracture Non-spine fracture Spine fracture 
Busselton 
Health Study2 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.7-1.8ng/dL (9-23pmol/L) 
or missing fT4 (1/89, 1.1%) 
TSH < 0.45mIU/L & normal fT4 0.7-
1.8ng/dL (9-23pmol/L) or missing fT4 (1/53, 
1.9%). fT3 value not available for SA 
ICD10: S72.0-1 Non-spine or spine 
fracture (first event) 
Including: ICD9: 807-829
Excluding: skull/face 
(ICD9: 800-804) 
Cervical (ICD10: S12), thoracic (ICD10: S22), 
lumbar (ICD10: S32) vertebrae, vertebral fracture of 
unknown location (ICD10: T08); clinically diagnosed 
Cardiovascular 
Health Study3 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.7-1.7ng/dL (9-22pmol/L) 
or missing fT4 (0/543, 4.2%) 
TSH < 0.45mIU/L & normal fT4 0.7-
1.7ng/dL (9-22pmol/L) or missing fT4 
(96/159, 60.4%) b. fT3 value not available 
for SA 
ICD9: 820.0-820.9 for 
inpatients, plus CPT 
procedure code on 
fracture treatment for 
outpatients d 
NA NA NA 
EPIC-Norfolk 
Study4 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.7-1.6ng/dL (9-20pmol/L) 
or missing fT4 (0/720, 0%) 
TSH < 0.45mIU/L & normal fT4 0.7-
1.6ng/dL (9-20pmol/L) or missing fT4 
(0/360, 0%). fT3 value not available for SA 
ICD10: S72.0-2 Non-spine or spine 
fracture (first event) 
Excluding skull/face, 
ankle, fingers, toes 
Thoracic (ICD10: S22) or lumbar (ICD10: S32) 
vertebrae, vertebral fracture of unknown location 
(ICD10: T08); clinically diagnosed 
Health, ABC 
Study5 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.8-1.8ng/dL (10-
23pmol/L) or missing fT4 (230/335, 
68.7%) c 
TSH < 0.45mIU/L & normal fT4 0.8-
1.8ng/dL (10-23pmol/L) or missing fT4 
(57/82, 69.5%). fT3 value not available for 
SA c 
Femoral neck, 
intertrochanteric, 
proximal femur 
Non-spine or spine 
fracture (first event) 
Excluding ankle, fingers, 
toes 
Thoracic or lumbar vertebrae; clinically diagnosed 
HUNT Study6 TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.6-1.6ng/dL (8-20pmol/L) 
or missing fT4 (0/814, 0%) 
TSH < 0.45mIU/L & normal fT4 0.6-
1.6ng/dL (8-20pmol/L) or missing fT4 
(556/945, 58.8%) a, & normal total T3 1.2-
2.7nmol/L (only in SA) 
ICD9: 824, SIFF-96 
procedure codes e; 
ICD10: S72.0-2, 
S72.9, NCSP codes f 
NA NA NA 
Invecchiare in 
Chianti Study 
(InCHIANTI)7 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.8-2.2ng/dL (10-
27pmol/L) or missing fT4 (0/33, 0%) 
TSH < 0.45mIU/L & normal fT4 0.8-
2.2ng/dL (10-27pmol/L) or missing fT4 
(0/86, 0%), & normal fT3 4.3-8.1pmol/L 
(only in SA) 
ICD9: 820 Non-spine or spine 
fracture (first event) 
Excluding skull/face, 
ankle, fingers, toes 
Thoracic (ICD9: 805.2-5) or lumbar (ICD9: 806.2-5) 
vertebrae; clinically diagnosed 
Leiden 85-plus 
Study8 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 1.0-1.8ng/dL (13-
23pmol/L) or missing fT4 (1/35, 2.9%) 
TSH < 0.45mIU/L & normal fT4 1.0-
1.8ng/dL (13-23pmol/L) or missing fT4 
(0/23, 0%), & normal fT3 4.7-8.2pmol/L 
(only in SA) 
Any hip fracture Any fracture NA NA 
Osteoporotic 
Fractures in 
Men (MrOS) 
Study9 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.7-1.85ng/dL (9-
24pmol/L) or missing fT4 (0/147, 0%) 
TSH < 0.45mIU/L & normal fT4 0.7-
1.85ng/dL (9-24pmol/L) or missing fT4 
(0/30, 0%). fT3 value not available for SA 
Femoral neck, 
intertrochanteric, 
subtrochanteric 
fracture 
Non-spine or spine 
fracture (first event) 
Excluding skull/face, 
ankle, fingers, toes 
Thoracic or lumbar vertebrae; clinically diagnosed 
Nagasaki Adult 
Health Study10 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.8-2.5ng/dL (10-
32pmol/L) or missing fT4 (0/420, 0%) 
TSH < 0.45mIU/L & normal fT4 0.8-
2.5ng/dL (10-32pmol/L) or missing fT4 (0/0, 
0%). fT3 value not available for SA 
Any hip fracture NA NA NA 
Osteoporosis 
and Ultrasound 
Study (OPUS)11 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.7-1.8ng/dL (9-23pmol/L) 
or missing fT4 (0/12, 0%) 
TSH < 0.45mIU/L & normal fT4 0.7-
1.8ng/dL (9-23pmol/L) or missing fT4 
(1/204, 0.5%), & normal fT3 2.5-5.7pmol/L 
(only in SA) 
Any low-traumatic hip 
fracture 
NA Any low-traumatic non-
spine fracture 
NA 
PROSPER 
Study12 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.9-1.4ng/dL (12-
18pmol/L) or missing fT4 (12/306, 
3.9%) 
TSH < 0.45mIU/L & normal fT4 0.9-
1.4ng/dL (12-18pmol/L) or missing fT4 
(7/133, 5.3%). fT3 value not available for 
SA 
NA Any fracture NA NA 
Rotterdam 
Study13 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.9-1.9ng/dL (11-
25pmol/L) or missing fT4 (35/107, 
32.7%) 
TSH < 0.45mIU/L & normal fT4 0.9-
1.9ng/dL (11-25pmol/L) or missing fT4 
(27/120, 22.5%). fT3 value not available for 
SA 
Any hip fracture Non-spine or spine 
fracture (first event) 
Excluding skull, 
ankle/foot, 
fingers/hand/wrist 
Any vertebral fracture; clinically diagnosed 
Sheffield 
Study14 
TSH ≥ 4.5mIU/L & TSH < 20mIU/L 
normal fT4 0.9-1.7ng/dL (12-
22pmol/L) or missing fT4 (0/32, 0%) 
TSH < 0.45mIU/L & normal fT4 0.9-
1.7ng/dL (12-22pmol/L) or missing fT4 
(0/11, 0%). fT3 value not available for SA 
Any hip fracture NA Any non-spine fracture NA 
 
Abbreviations: CPT, current procedural terminology; fT3, free triiodothyronine; fT4, free thyroxine; NA, not available; TSH, thyroid-stimulating hormone; y, years. 
a fT4 was measured only in participants with TSH < 0.20mIU/L 
b fT4 was measured only in participants with TSH ≤ 0.10mIU/L 
c fT4 was measured only in participants with TSH ≤ 0.10mIU/L or TSH ≥ 7.00mIU/L 
d CPT procedure codes 27125-27127, 27130-27131, 27230-27248, 29010-29046, 29305-29365, 29505-29520, 29799. 
e Third Norwegian national classification of surgical procedures (SIFF-96) codes 8072, 8073, 8079, 8103, 8106, 8332, 8334, 8336 and 8339 
f Nomesco Classification of Surgical Procedures (NCS) codes NFB 00-03, 09-13, 19-20, 30, 40, 59, 99, NFJ 00-03, 10-13, 20-23, 30-33, 40-43, 50-55, 60-63, 70-73, 80-83, 90-93, TNF40 
g For spine fractures, cervical and sacral fractures were excluded when data allowed, as these fractures usually occur in high-energy trauma. For other fracture outcomes, data on trauma mechanism were generally unavailable. 
  
eTable 2: Quality Assessment of Included Studies a 
Study  Design Setting Ascertainment of exposure b 
Controlling for 
the most 
important 
factors c 
Controlling for any 
additional factors c Methods for fracture assessment 
Formal 
adjudication 
of fractures d
Adjudication 
blinded to 
thyroid 
status 
Loss to 
follow-
up 
Duration 
of follow-
up, 
median 
(IQR) 
Busselton Health Study Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
medication, anti-osteoporotic 
medication 
Hospital discharge records: diagnoses 
coded with ICD9 and ICD10 
no NA 5% 20.0 
(17.2-20.0
) 
Cardiovascular Health 
Study 
Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
and thyroid-altering 
medication, anti-osteoporotic 
medication 
Interview and hospital records reviewed by 
experts 
no NA 0% 12.8 
(7.5-18.8) 
EPIC-Norfolk Study Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
and thyroid-altering 
medication 
Hospital discharge coding by data linkage 
with NHS central register 
yes  yes 1.3% 12.4 
(11.6-13.3
) 
Health ABC Study Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
and thyroid-altering 
medication, anti-osteoporotic 
medication 
Interview, hospital records, and other 
support documents reviewed by a panel of 
clinicians 
yes yes  <5% 12.8 
(8.1-13.2) 
HUNT Study Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid or 
thyroid-altering medication 
Hospital records and radiology reports 
reviewed by physicians, health secretaries 
and nurses 
yes yes <5% 12.2 
(11.6-12.8
) 
Invecchiare in Chianti 
(InCHIANTI) Study 
Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
and thyroid-altering 
medication, anti-osteoporotic 
medication 
Hospital records and other support 
documents 
yes yes <5% 9.1 
(7.2-9.3) 
Leiden 85-plus Study Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
and thyroid-altering 
medication, anti-osteoporotic 
medication 
Annual interview of treating general 
practitioner or nursing home physician and 
review of all medical records of general 
practitioners / nursing home physicians 
no NA <4% 4.9 
(2.2-8.2) 
Osteoporotic Fractures 
in Men (MrOS) Study 
Random 
sample of a 
prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
and thyroid-altering 
medication, anti-osteoporotic 
medication 
Interview-reported fractures centrally 
adjudicated by physician through radiology 
reports or X-rays 
yes yes 2% 11.1 
(8.0-11.8) 
Nagasaki Adult Health 
Study 
Prospective 
cohort study 
Population-
based 
First generation 
TSH assay e 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
medication 
Interview of participants no NA 7.3% 20.2 
(10.0-25.9
) 
Osteoporosis and 
Ultrasound Study 
(OPUS) 
Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
Thyroid and thyroid-altering 
medication, anti-osteoporotic 
medication 
Interview after 6y follow-up, validated 
through medical records and imaging 
reviewed by a radiologist 
yes yes 40% 6.0 
(5.8-6.3) 
PROSPER Study Prospective 
cohort study f 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
and thyroid-altering 
medication 
Fractures documented as adverse events no NA <1% 3.2 
(3.0-3.5) 
Rotterdam Study Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
medication 
General practitioner and hospital registry 
records, reviewed by independent medical 
experts in the field 
yes yes <1% 15.2 
(10.2-16.2
) 
Sheffield Study Prospective 
cohort study 
Population-
based 
Third 
generation  
TSH assay 
Age, gender, 
BMI, smoking 
status 
History of diabetes, thyroid 
medication 
General practitioner records, and interview, 
if confirmed by radiology or orthopedic 
report 
yes  yes 2% 10.0 
(5.3-10.1) 
 
Abbreviations: BMI, body mass index; IQR, interquartile range; NA, not applicable; TSH, thyroid-stimulating hormone 
a Based on the individual items of the Newcastle-Ottawa Quality Assessment Scale1. Absence of the outcome at baseline was not included in this list as participants with acute fracture at baseline were excluded from the analysis. 
b Third generation TSH assays have a functional sensitivity of 0.01-0.02mIU/l (the lowest TSH level at which interassay coefficient of variation is <20%), making this a highly precise measurement. 
c By design the individual participant data analysis allowed the adjustment of multiple factors done in a stepwise manner: primary analyses and the multivariable model (left column), followed by sensitivity analyses (right column). 
d Formal adjudication was defined as formal report by each cohort on application of predefined criteria by experts to each fracture event. 
e The Nagasaki Adult Health Study used a first generation TSH assay and was excluded from the analysis on subclinical hyperthyroidism. 
f Based on both arms of a randomized controlled trial of Pravastatin vs. Placebo, without any intervention on thyroid function.  
eTable 3: Stratified analyses for the association between subclinical hyperthyroidism and the risk of fractures 
  Hip fracture 
a Any fracture b 
  Euthyroidism Subclinical Hyperthyroidism HR (95% CI) Euthyroidism 
Subclinical 
Hyperthyroidism HR (95% CI) 
  Events Participants Events Participants Age/Sex-adjusted Multivariable Model e Events Participants Events Participants Age/Sex-adjusted Multivariable Model e 
Total population 2534 56,471 146 2082 1.36 (1.13-1.64) 1.37 (1.11-1.70) 2203 25,901 121 888 1.28 (1.06-1.53) 1.27 (1.06-1.53) 
Sex       
Men 606 21,854 22 468 1.92 (1.26-2.94) 1.96 (1.28-3.00) 796 13,091 32 327 1.69 (1.18-2.41) 1.73 (1.21-2.47) 
Women 1928 34,617 124 1614 1.29 (1.08-1.55) 1.28 (1.04-1.58) 1407 12,810 89 561 1.21 (0.98-1.51) 1.21 (0.97-1.50) 
P for interaction 0.09 0.08   0.12 0.10 
Age f       
< 75 years 1360 47,540 78 1646 1.54 (1.22-1.93) 1.59 (1.19-2.12) 1363 20,067 69 649 1.33 (1.04-1.69) 1.32 (1.04-1.69) 
≥ 75 years 1162 8462 67 431 1.22 (0.95-1.56) 1.21 (0.93-1.56 840 5834 52 239 1.24 (0.93-1.65) 1.22 (0.92-1.63) 
P for interaction 0.18 0.17   0.72 0.68 
TSH       
0.45-4.49 mIU/L 2534 56,471 1 (ref) 1 (ref) 2203 25,901 1 (ref) 1 (ref) 
0.10-0.44 mIU/L 99 1568 1.34 (1.01-1.77) 1.33 (1.01-1.76)   77 676 1.10 (0.87-1.38) 1.10 (0.87-1.38) 
< 0.10 mIU/L 47 510 1.61 (1.21-2.15) 1.57 (1.17-2.10)   44 212 1.98 (1.41-2.78) 1.92 (1.37-2.69) 
P for trend 0.001 0.003         < 0.001 < 0.001 
  Non-spine fracture 
c Spine fracture d 
Total population 1745 21,722 107 946 1.16 (0.95-1.41) 1.16 (0.95-1.41) 255 20,328 17 732 1.51 (0.93-2.45) 1.49 (0.92-2.42) 
Sex         
Men 592 10,326 24 282 1.53 (1.01-2.31) 1.56 (1.03-2.37) 106 10,332 7 282 3.61 (1.76-7.41) 3.78 (1.83-7.80) 
Women 1153 11,396 83 664 1.10 (0.88-1.37) 1.10 (0.88-1.38) 149 9996 10 450 1.17 (0.63-2.19) 1.16 (0.62-2.16) 
P for interaction   0.17 0.15   0.02 0.02 
Age f         
< 75 years 1218 18,707 69 766 1.17 (0.85-1.59) 1.18 (0.87-1.61) 167 17,476 9 581 1.64 (0.87-3.10) 1.58 (0.83-2.97) 
≥ 75 years 527 2847 36 175 1.08 (0.77-1.53) 1.07 (0.75-1.52) 86 2732 8 148 1.83 (0.89-3.79) 1.88 (0.91-3.89) 
P for interaction   0.74 0.68   0.82 0.73 
TSH         
0.45-4.49 mIU/L 1745 21,722 1 (ref) 1 (ref) 255 20,328 1 (ref) 1 (ref) 
0.10-0.44 mIU/L   74 757 1.02 (0.81-1.29) 1.03 (0.81-1.30)   9 566 1.12 (0.59-2.13) 1.15 (0.61-2.17) 
< 0.10 mIU/L   32 185 1.61 (0.96-2.71) 1.59 (0.94-2.70)   8 162 3.57 (1.88-6.78) 3.31 (1.71-6.41) 
P for trend   0.07 0.08         < 0.001 < 0.001 
 
Abbreviations: CI, confidence interval; HR, hazard ratio; TSH, thyroid-stimulating hormone 
a The PROSPER study was not included because follow-up data were only available for any fracture  
b The HUNT, Cardiovascular Health Study, Sheffield and OPUS  studies were not included because follow-up data for any fracture were not available. 
c The HUNT, Cardiovascular Health Study, Leiden 85-plus and PROSPER studies were not included because follow-up data for non-spine fractures were not available.  
d The HUNT, Cardiovascular Health Study, Leiden 85-plus, Sheffield, OPUS and PROSPER studies were not included because follow-up data for spine fractures were not available.  
e Adjusted for age, sex, body mass index and smoking status. Complete case analysis was used, as missing data rate was <3% and unlikely to introduce relevant bias into the multivariable models15,16.  
f These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.  
eTable 4: Sensitivity analyses on the association between subclinical hyperthyroidism and the risk of fractures  
  Hip fracture Any fracture 
  Euthyroidism Subclinical Hyperthyroidism HR (95% CI) Euthyroidism 
Subclinical 
Hyperthyroidism HR (95% CI) 
  Events Participants Events Participants   Events Participants Events Participants   
All eligible studies    
Random-effects model 2534 56,471 146 2082 1.36 (1.13-1.64) 2203 25,901 121 888 1.28 (1.06-1.53)
Fixed-effects model 2534 56,471 146 2082 1.35 (1.14-1.60) 2203 25,901 121 888 1.28 (1.07-1.54)
Definition of Subclinical Hyperthyroidism       
Excluding those with missing FT4 2534 56,471 77 1344 1.39 (1.10-1.76) 2203 25,901 94 796 1.31 (1.07-1.62)
Excluding those with abnormal free or total T3 2500 56,015 143 2021 1.38 (1.11-1.71) 2139 25,445 117 857 1.28 (1.06-1.55)
Applying age-specific TSH reference ranges a 2373 55,166 196 2438 1.32 (1.14-1.53) 2044 24,813 151 1104 1.23 (1.04-1.45)
Medication use       
Excluding users of thyroid medication at baseline b 2414 54,737 87 1430 1.52 (1.19-1.93) 2113 25,177 99 710 1.42 (1.16-1.74)
Excluding users of thyroid medication at baseline or during follow-up b 2381 54,464 83 1399 1.54 (1.19-1.99) 2092 25,043 94 684 1.42 (1.15-1.75)
Excluding users of thyroid and thyroid-altering medication b 2341 53,378 83 1385 1.47 (1.18-1.83) 2048 24,649 95 689 1.39 (1.13-1.71)
Excluding users of anti-osteoporotic medication at baseline c 2516 56,303 144 2063 1.39 (1.12-1.72) 2162 25,759 115 873 1.27 (1.05-1.54)
Outcomes       
Only studies with formal adjudication procedures d 2078 51,255 109 1847 1.36 (1.01-1.81) 1568 18,420 98 686 1.29 (1.05-1.58)
Only studies with most uniform definition of fracture 2534 56,471 146 2082 1.36 (1.13-1.64) 1650 22,383 82 715 1.35 (1.08-1.69)
Excluded Studies            
Excluding study inconsistent with proportional hazard assumption e NA NA NA NA NA NA NA NA NA NA 
Excluding small study because of potential publication bias f 2531 56,186 145 2071 1.33 (1.13-1.58) NA NA NA NA NA 
Excluding study with >5% loss to follow-up g 2528 55,299 145 1870 1.38 (1.12-1.70) NA NA NA NA NA 
Excluding study with less objective outcome ascertainment h NA NA NA NA NA 1824 20,783 104 755 1.26 (1.03-1.53)
Further adjustments of multivariable models       
Plus history of diabetes mellitus at baseline 2395 53,731 137 1793 1.38 (1.09-1.75) 2 163 25,442 120 859 1.27 (1.05-1.53)
  Non-spine fracture Spine fracture 
All eligible studies             
Random-effects model 1745 21,722 107 946 1.16 (0.95-1.41) 255 20,328 17 732 1.51 (0.93-2.45)
Fixed-effects model 1745 21,722 107 946 1.16 (0.95-1.41) 255 20,328 17 732 1.51 (0.93-2.45)
Definition of Subclinical Hyperthyroidism         
Excluding those with missing FT4 1745 21,722 86 860 1.18 (0.95-1.47) 255 20,328 11 647 1.90 (0.98-3.68)
Excluding those with abnormal free or total T3 1745 21,722 106 910 1.17 (0.96-1.43) 255 20,328 17 724 1.51 (0.93-2.46)
Applying age-specific TSH reference ranges a 1638 21,078 132 1099 1.13 (0.94-1.35) 235 19,724 21 856 1.48 (0.95-2.30)
Medication use         
Excluding users of thyroid medication at baseline b 1675 21,137 89 779 1.26 (1.00-1.61) 240 19,745 13 567 1.74 (1.01-2.99)
Excluding users of thyroid medication at baseline or during follow-up b 1660 21,030 86 764 1.24 (1.00-1.55) 236 19,645 12 553 1.65 (0.94-2.91)
Excluding users of thyroid and thyroid-altering medication b 1617 20,634 85 758 1.23 (0.98-1.53) 232 19,242 13 546 1.79 (1.04-3.09)
Excluding users of anti-osteoporotic medication at baseline c 1703 21,567 103 927 1.17 (0.96-1.44) 246 20,191 15 717 1.45 (0.87-2.42)
Outcomes         
Only studies with formal adjudication procedures d 1583 19,827 105 893 1.18 (0.96-1.44) 239 18,421 17 679 1.52 (0.93-2.49)
Only studies with most uniform definition of fracture 1596 20,315 88 732 1.19 (0.96-1.48) 174 16,810 10 559 1.65 (0.89-3.07)
Excluded Studies         
Excluding study inconsistent with proportional hazard assumption e 1646 20,600 91 743 1.21 (0.98-1.50) NA NA NA NA NA 
Excluding small study because of potential publication bias f NA NA NA NA NA NA NA NA NA NA 
Excluding study with >5% loss to follow-up g 1646 20,600 91 743 1.21 (0.98-1.50) NA NA NA NA NA 
Excluding study with less objective outcome ascertainment h NA NA NA NA NA NA NA NA NA NA 
Further adjustments of multivariable models         
Plus history of diabetes mellitus at baseline 1610 20,163 90 715 1.20 (0.97-1.49) 252 19,889 17 704 1.51 (0.93-2.45)
 
Abbreviations: CI, confidence interval; FT4, free thyroxine; HR, hazard ratio (all age and sex adjusted, except for the last row); NA, data not applicable (no cohorts concerned by this sensitivity analysis); T3, triiodothyronine 
a The TSH reference range for euthyroidism changed according to age group, as previously published17: TSH reference range was 0.45-4.49mIU/L for participants <75 years, 0.71-2.67mIU/L for 75-79.9 years, 0.60-6.16mIU/L for 
80-84.9 years, 0.51-6.41mIU/L for 85-89.9 years, and 0.20-7.96mIU/L for participants aged 90 years or older.  
b Thyroid medication includes thyroxine and anti-thyroid drugs; thyroid-altering medication includes oral corticosteroids, amiodarone and iodine. 
c Anti-osteoporotic medication includes bisphosphonates, calcitonin, selective estrogen receptor modulator, parathyroid hormone. 
d Formal adjudication procedures were defined as having clear criteria for the outcomes that were reviewed by experts for each potential case, which was performed in 8 studies. 
e Excluding the Osteoporosis and Ultrasound study for non-spine fracture outcome (p=0.02). 
f Excluding the Sheffield study for hip fracture outcome, which might be an outlier with no corresponding study of similar size with reduced fracture risk associated with subclinical hyperthyroidism (p=0.30). 
g Excluding the Osteoporosis and Ultrasound study. 
h Excluding the PROSPER study, which did not ascertain fractures with independent blind assessment or record linkage. 
  
eTable 5: Persistent thyroid function state and fracture risk 
A. Availability of repeated thyroid function testing data and persistent thyroid function state 
Study 
Participants 
Interval to follow-up thyroid 
function test Baseline thyroid 
function test 
Follow-up thyroid function 
test 
Persistent thyroid 
function state a 
Cardiovascular Health Study 3555 2382 2073 4 years 
HUNT Study 33,646 18,582 17,145 12 years 
Leiden 85-plus Study 514 383 353 2 years 
PROSPER Study 5563 5181 4836 6 months 
Busselton Health Study 2049 1187 1090 13 years 
     
B. Association between persistent subclinical thyroid dysfunction and risk of fractures 
 Persistent euthyroidism 
Persistent subclinical thyroid 
dysfunction HR (95% CI) 
 Events Participants Events Participants 
Persistent subclinical hyperthyroidism      
   Hip fracture 562 20,069 12 251 1.25 (0.58-2.65) 
   Any fracture 465 5943 12 93 1.48 (0.84-2.61) 
      
Persistent subclinical hypothyroidism      
   Hip fracture 562 20,069 32 341 1.36 (0.55-3.33) 
   Any fracture 465 5943 21 238 1.06 (0.68-1.63) 
 
Abbreviations: CI, confidence interval; HR, hazard ratio 
a Persistent thyroid function state is defined as persistent category (subclinical hypothyroidism, euthyroidism, subclinical hyperthyroidism) from baseline to follow-up thyroid function test  
eTable 6: Analysis stratified by publication status of fracture data 
A. Subclinical Hyperthyroidism                         
  Hip fracture Any fracture 
  
Euthyroidism Subclinical Hyperthyroidism HR (95% CI) 
P for 
interaction Euthyroidism 
Subclinical 
Hyperthyroidism HR (95% CI) 
P for 
interaction
  Events Participants Events Participants     Events Participants Events Participants     
All studies 2534 56,471 146 2082 1.36 (1.13-1.64)   2203 25,901 121 888 1.28 (1.06-1.53)   
Excluding unpublished studies 2445 53,498 139 1942 1.35 (1.09-1.67) 0.45 1545 17,810 93 615 1.28 (1.04-1.58) 0.81 
Excluding published studies 89 2973 7 140 1.84 (0.85-3.98) 658 8091 28 273 1.20 (0.73-1.95)
  Non-spine fracture Spine fracture 
All studies 1745 21,722 107 946 1.16 (0.95-1.41)   255 20,328 17 732 1.51 (0.93-2.45)   
Excluding unpublished studies 1503 18,761 96 806 1.15 (0.94-1.42) 0.72 229 17,355 17 592 1.56 (0.94-2.56) 0.69 
Excluding published studies 242 2961 11 140 0.93 (0.30-2.92) 23 2973 0 140 0.89 (0.11-7.26)
B. Subclinical Hypothyroidism                         
  Hip fracture Any fracture 
  Euthyroidism 
Subclinical 
Hypothyroidism HR (95% CI) 
P for 
interaction Euthyroidism 
Subclinical 
Hypothyroidism HR (95% CI) 
P for 
interaction
  Events Participants Events Participants     Events Participants Events Participants     
All studies 2600 58,637 229 3759 0.96 (0.83-1.10)   2203 25,901 204 1772 1.02 (0.89-1.18)   
Excluding unpublished studies 2445 53,498 213 3243 0.95 (0.83-1.10) 0.82 1545 17,810 153 1344 0.96 (0.81-1.14) 0.15 
Excluding published studies 155 5139 16 516 1.05 (0.45-2.43) 658 8091 51 428 1.23 (0.92-1.64)
  Non-spine fracture Spine fracture 
All studies 1745 21,722 166 1473 1.06 (0.90-1.24)   255 20,328 24 1431 0.96 (0.59-1.55)   
Excluding unpublished studies 1503 18,761 147 1352 1.04 (0.86-1.25) 0.34 229 17,355 22 1309 0.92 (0.52-1.63) 0.47 
Excluding published studies 242 2961 18 121 1.34 (0.83-2.14) 23 2973 2 122 1.64 (0.38-7.02)
 
Abbreviations: CI, confidence interval; HR, hazard ratio 
The following studies have not previously published their fracture data: Busselton Health Study, Invecchiare in Chianti (InCHIANTI) Study, Nagasaki Adult Health Study, PROSPER Study. 
P for interaction values are calculated for comparing HR and 95% CI between published studies vs. unpublished studies.
eTable 7: Stratified analyses for the association between subclinical hypothyroidism and the risk of fractures 
  Hip fracture a Any fracture b
  Euthyroidism Subclinical Hypothyroidism HR (95% CI) Euthyroidism Subclinical Hypothyroidism HR (95% CI) 
  Events Participants Events Participants Age/Sex-adjusted Multivariable Model e Events Participants Events Participants Age/Sex-adjusted Multivariable Model e
Total population 2600 58,637 229 3759 0.96 (0.83-1.10) 0.98 (0.85-1.14) 2203 25,901 204 1772 1.02 (0.89-1.18) 1.05 (0.90-1.24) 
Sex       
Men 617 22,691 50 1202 0.99 (0.74-1.33) 1.07 (0.80-1.43) 796 13,091 53 681 0.90 (0.68-1.20) 0.92 (0.69-1.22) 
Women 1983 35,946 179 2557 0.98 (0.82-1.16) 1.00 (0.81-1.23) 1407 12,810 151 1091 1.09 (0.92-1.29) 1.12 (0.92-1.36) 
P for 
interaction 0.95 0.71   0.25 0.27 
Age f       
< 75 years 1418 49,854 114 2856 0.94 (0.77-1.14) 0.93 (0.76-1.14) 1363 20,067 112 1252 1.06 (0.84-1.32) 1.10 (0.84-1.43) 
≥ 75 years 1177 8613 115 897 0.99 (0.82-1.21) 1.05 (0.86-1.29) 840 5834 92 520 1.01 (0.81-1.26) 1.01 (0.81-1.27) 
P for 
interaction 0.71 0.40   0.77 0.63 
TSH       
0.45-4.49 
mIU/L 2600 58,637 1 (ref) 1 (ref) 2203 25,901 1 (ref) 1 (ref) 
4.50-6.99 
mIU/L 168 2696 0.99 (0.85-1.16) 1.02 (0.87-1.20)   148 1229 1.11 (0.91-1.35) 1.13 (0.91-1.39) 
7.00-9.99 
mIU/L 38 676 0.92 (0.67-1.27) 1.01 (0.63-1.62)   37 344 1.04 (0.75-1.44) 1.09 (0.77-1.53) 
10-19.99 
mIU/L 23 365 1.17 (0.78-1.76) 1.22 (0.80-1.87)   18 183 0.88 (0.48-1.62) 0.93 (0.52-1.67) 
P for trend 0.54 0.40         0.64 0.78 
  Non-spine fracture c Spine fracture d 
Total population 1745 21,722 166 1473 1.06 (0.90-1.24) 1.12 (0.91-1.38) 255 20,328 24 1431 0.96 (0.59-1.55) 1.00 (0.59-1.71) 
Sex         
Men 592 10,326 40 569 0.87 (0.63-1.20) 0.88 (0.63-1.21) 106 10,332 7 569 1.08 (0.46-2.52) 1.21 (0.45-3.24) 
Women 1153 11,396 126 904 1.17 (0.96-1.42) 1.24 (0.97-1.60) 149 9996 17 862 1.11 (0.62-1.99) 1.13 (0.60-2.13) 
P for 
interaction   0.13 0.11   0.96 0.91 
Age f         
< 75 years 1218 18,707 101 1143 1.18 (0.89-1.56) 1.22 (0.89-1.67) 167 17,476 10 1106 0.85 (0.45-1.61) 0.85 (0.45-1.62) 
≥75 years 480 2732 63 319 1.00 (0.77-1.30) 1.00 (0.77-1.31) 88 2852 14 325 1.61 (0.74-3.51) 1.41 (0.68-2.95) 
P for 
interaction   0.40 0.34   0.21 0.31 
TSH         
0.45-4.49 
mIU/L 1745 21,722 1 (ref) 1 (ref) 255 20,328 1 (ref) 1 (ref) 
4.50-6.99 
mIU/L   121 1003 1.23 (0.94-1.60) 1.25 (0.95-1.65)   15 974 0.88 (0.51-1.52) 0.95 (0.50-1.82) 
7.00-9.99 
mIU/L   27 288 0.97 (0.66-1.42) 1.03 (0.64-1.66)   7 288 1.58 (0.76-3.29) 1.67 (0.80-3.47) 
10-19.99 
mIU/L   17 167 1.01 (0.60-1.70) 1.05 (0.63-1.76)   2 160 2.08 (0.66-6.49) 2.17 (0.73-6.44) 
P for trend   0.80 0.96         0.13 0.10 
 
Abbreviations: CI, confidence interval; HR, hazard ratio; TSH, thyroid-stimulating hormone. 
a The PROSPER study was not included because follow-up data were only available for any fracture 
b The HUNT, Cardiovascular Health Study, Sheffield and OPUS studies were not included because follow-up data for any fracture were not available. 
c The HUNT, Cardiovascular Health Study, Leiden 85-plus and PROSPER studies were not included because follow-up data for non-spine fractures were not available. 
d The HUNT, Cardiovascular Health Study, Leiden 85-plus, Sheffield, OPUS and PROSPER studies were not included because follow-up data for spine fractures were not available. 
e Adjusted for age, sex, body mass index and smoking status. Complete case analysis was used, as missing data rate was <3% and unlikely to introduce relevant bias into the multivariable models15,16. 
f These HRs were adjusted for sex and age as a continuous variable to avoid residual confounding within age strata.  
eTable 8: Sensitivity analyses on the association between subclinical hypothyroidism and the risk of fractures 
  Hip fracture Any fracture 
  Euthyroidism Subclinical Hypothyroidism HR (95% CI) Euthyroidism Subclinical Hypothyroidism HR (95% CI) 
  Events Participants Events Participants   Events Participants Events Participants   
All eligible studies     
Random-effects model 2600 58,637 229 3759 0.96 (0.83-1.10) 2203 25,901 204 1772 1.02 (0.89-1.18) 
Fixed-effects model 2600 58,637 229 3759 0.96 (0.83-1.10) 2203 25,901 204 1772 1.02 (0.89-1.18) 
Definition of Subclinical Hypothyroidism       
Excluding those with missing FT4 2600 58,637 206 3492 0.95 (0.82-1.10) 2203 25,901 138 1493 0.98 (0.83-1.17) 
Medication use       
Excluding users of thyroid medication at baseline a 2480 56,878 207 3325 0.98 (0.85-1.13) 2113 25,177 179 1557 1.04 (0.89-1.21) 
Excluding users of thyroid medication at baseline or during follow-up a 2447 56,605 173 2999 1.02 (0.87-1.19) 2092 25,043 157 1397 1.11 (0.94-1.30) 
Excluding users of thyroid and thyroid-altering medication a 2407 55,519 201 3259 0.97 (0.83-1.12) 2048 24,649 175 1516 1.06 (0.90-1.23) 
Excluding users of anti-osteoporotic medication at baseline b 2582 58,469 228 3745 0.96 (0.84-1.10) 2162 25,759 199 1759 1.03 (0.89-1.19) 
Outcomes       
Only studies with formal adjudication procedures c 2078 51,255 139 2698 0.93 (0.78-1.10) 1568 18,420 175 1342 1.00 (0.85-1.18) 
Only studies with most uniform definition of fracture 2600 58,637 229 3759 0.96 (0.83-1.10) 1650 22,383 156 1576 0.97 (0.82-1.15) 
Excluded Studies       
Excluding study inconsistent with proportional hazard assumption d NA NA NA NA NA NA NA NA NA NA 
Excluding small study because of potential publication bias e 2594 57,465 229 3747 0.95 (0.83-1.09) NA NA NA NA NA 
Excluding studies with >5% loss to follow-up f 2528 55,299 222 3353 0.97 (0.84-1.12) NA NA NA NA NA 
Excluding studies with less objective outcome ascertainment g 2534 56,471 222 3365 0.97 (0.85-1.12) 1806 20,783 174 1466 1.01 (0.86-1.18) 
Further adjustments of multivariable models       
Plus history of diabetes mellitus at baseline 2457 55,746 216 3631 0.98 (0.85-1.13) 2163 25,442 203 1745 1.06 (0.90-1.24) 
 Non-spine fracture Spine fracture 
All eligible studies               
Random-effects model 1745 21,722 166 1473 1.06 (0.90-1.24) 255 20,328 24 1431 0.96 (0.59-1.55) 
Fixed-effects model 1745 21,722 166 1473 1.06 (0.90-1.24) 255 20,328 24 1431 0.92 (0.60-1.40) 
Definition of Subclinical Hypothyroidism         
Excluding those with missing FT4 1745 21,722 106 1207 1.03 (0.81-1.31) 255 20,328 13 1165 0.92 (0.52-1.62) 
Medication use         
Excluding users of thyroid medication at baseline a 1675 21,137 143 1304 1.05 (0.88-1.25) 240 19,745 21 1263 1.06 (0.59-1.91) 
Excluding users of thyroid medication at baseline or during follow-up a 1660 21,030 125 1163 1.13 (0.93-1.38) 236 19,645 18 1130 1.16 (0.66-2.04) 
Excluding users of thyroid and thyroid-altering medication a 1617 20,634 140 1269 1.06 (0.89-1.26) 232 19,242 20 1228 1.07 (0.58-1.96) 
Excluding users of anti-osteoporotic medication at baseline b 1703 21,567 161 1461 1.06 (0.90-1.25) 245 20,191 22 1419 0.97 (0.56-1.68) 
Outcomes         
Only studies with formal adjudication procedures c 1583 19,827 153 1385 1.05 (0.88-1.27) 239 18,421 23 1342 0.99 (0.57-1.74) 
Only studies with most uniform definition of fracture 1596 20,315 156 991 1.02 (0.86-1.20) 174 16,810 16 1235 0.89 (0.45-1.79) 
Excluded Studies         
Excluding study inconsistent with proportional hazard assumption d NA NA NA NA NA 190 18,717 17 1324 0.82 (0.47-1.43) 
Excluding small study because of potential publication bias e NA NA NA NA NA 245 19,262 23 1398 0.90 (0.55-1.45) 
Excluding studies with >5% loss to follow-up f 1646 20,600 166 1461 1.07 (0.90-1.27) NA NA NA NA NA 
Excluding studies with less objective outcome ascertainment g NA NA NA NA NA NA NA NA NA NA 
Further adjustments of multivariable models         
Plus history of diabetes mellitus at baseline 1610 20,163 165 1 437 1.13 (0.92-1.40) 252 19,889 24 1407 1.01 (0.59-1.72) 
 
Abbreviations: CI, confidence interval; FT4, free thyroxine; HR, hazard ratio (all age and sex adjusted, except for the last row); NA, data not applicable (no cohorts concerned by this sensitivity analysis). 
a Thyroid medication includes thyroxine and anti-thyroid drugs; thyroid-altering medication includes oral corticosteroids, amiodarone and iodine. 
b Anti-osteoporotic medication includes bisphosphonates, calcitonin, selective estrogen receptor modulator, parathyroid hormone. 
c Formal adjudication procedures were defined as having clear criteria for the outcomes that were reviewed by experts for each potential case, which was performed in 8 studies. 
d Excluding the Rotterdam study for spine fracture outcome. 
e Excluding the Osteoporosis and Ultrasound Study (OPUS) for hip fracture outcome (p=0.57), and Invecchiare in Chianti Study (InChianti) for spine fracture outcome (p=0.21). 
f Excluding the Osteoporosis and Ultrasound study and the Nagasaki Adult Health Study. 
g Excluding the PROSPER study and the Nagasaki Adult Health Study, which did not ascertain fractures with independent blind assessment or record linkage. 
  
eTable 9: Analysis on the association of thyroid medication treatment and fracture risk (treated vs. untreated) 
 Use of thyroid medication No use of thyroid medication Age and sex-adjusted HR (95% CI) 
 Events Participants Events Participants 
Hip fracture 200 2781 2734 59,624 1.06 (0.92-1.23) 
Any fracture 135 1092 2382 27,396 0.98 (0.82-1.17) 
Non-spine fracture 109 900 1722 21,504 1.03 (0.85-1.26) 
Spine fracture 22 900 272 21,518 1.18 (0.76-1.83) 
 
Abbreviations: CI, confidence interval; HR, hazard ratio.  
eFigure 1: Flow Chart of Studies Evaluated for Inclusion in the Individual Participant Data 
Title: Flow Chart of Studies Evaluated for Inclusion in the Individual Participant Data (IPD) Analysis, adapted from the Flow Diagram in the PRISMA Statement18 
and from 19. 
Legend: a from prospective cohorts already participating to the Thyroid Studies Collaboration that confirmed having prospective data on fracture outcomes. 
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eFigure 2: Forest plots of the association between subclinical hypothyroidism and the risk of 25 
fractures 26 
 27 
Legend: Hip, any, non-spine and spine fractures in subclinical hypothyroidism vs. euthyroidism. Age and sex-adjusted hazard ratios (HR) and their 95% 28 
confidence intervals (CI) are represented by squares or diamonds. The sizes of the squares are proportional to the inverse of the variance of the HR. 29 
Not every outcome was available for each study. τ2 measures heterogeneity in effect estimates across cohorts, with a pre-specified τ2 of ≤0.04 30 
representing low heterogeneity and >0.04 to <0.36 representing moderate heterogeneity. EPIC: European Prospective Investigation of Cancer. HUNT: 31 
Nord-Trøndelag Health Study. 32 
  33 
  34 
Events,
No.
Participants,
No.
Events,
No.
Participants,
No.
Hip fracture
Cardiovascular Health Study 378 2853 76 543 1.03 (0.80-1.31) 30.8
Health, Aging and Body Composition Study 171 2347 22 335 0.82 (0.53-1.28) 9.5
Osteoporotic Fractures in Men Study (MrOS) 51 1411 7 147 1.14 (0.51-2.51) 3
EPIC-Norfolk Study 189 11,986 14 720 0.92 (0.53-1.58) 6.3
HUNT Study 1507 31377 82 1313 0.90 (0.72-1.12) 37.8
Invecchiare in Chianti Study 45 1066 3 33 1.15 (0.35-3.72) 1.4
Leiden 85-Plus Study 34 456 1 35 0.35 (0.05-2.53) 0.5
Osteoporosis and Ultrasound Study (OPUS) 6 1172 0 12 5.68 (0.25-131) 0.2
Rotterdam Study 106 1611 11 107 1.25 (0.67-2.34) 4.8
Sheffield Study 3 285 0 31 1.18 (0.04-37.1) 0.2
Busselton Health Study 44 1907 6 89 2.00 (0.84-4.75) 2.5
Nagasaki Adult Health Study 66 2166 7 394 0.54 (0.25-1.18) 3.1
Total (τ2 = 0.00) 2600 58,637 229 3759 0.96 (0.83-1.10) 100
Any fracture
Health, Aging and Body Composition Study 463 2347 64 335 0.89 (0.68-1.15) 30.4
Osteoporotic Fractures in Men Study (MrOS) 186 1411 21 147 1.00 (0.64-1.58) 10.1
EPIC-Norfolk Study 453 11,985 31 720 0.92 (0.64-1.32) 15.7
Invecchiare in Chianti Study 87 1066 7 33 1.71 (0.79-3.74) 3.4
Leiden 85-Plus Study 64 456 3 35 0.55 (0.17-1.75) 1.6
PROSPER Study 397 5118 30 306 1.13 (0.78-1.64) 15.1
Rotterdam Study 379 1611 34 107 1.20 (0.84-1.71) 16.8
Busselton Health Study 174 1907 14 89 1.25 (0.72-2.16) 6.9
Total (τ2 = 0.01) 2203 25,901 204 1772 1.02 (0.89-1.18) 100
Non-spine fracture
Health, Aging and Body Composition Study 400 2347 58 335 0.94 (0.71-1.24) 33.9
Osteoporotic Fractures in Men Study (MrOS) 161 1411 18 147 0.99 (0.60-1.61) 10.8
EPIC-Norfolk Study 444 11,985 30 720 0.90 (0.62-1.31) 18.8
Invecchiare in Chianti Study 80 1066 6 33 1.56 (0.67-3.61) 3.7
Osteoporosis and Ultrasound Study (OPUS) 99 1122 0 12 0.38 (0.02-6.20) 0.3
Rotterdam Study 349 1611 31 107 1.15 (0.80-1.67) 19
Sheffield Study 50 285 10 31 2.05 (1.04-4.05) 5.6
Busselton Health Study 162 1895 13 88 1.24 (0.70-2.20) 8
Total (τ2 = 0.00) 1745 21,722 166 1473 1.06 (0.90-1.24) 100
Spine fracture
Health, Aging and Body Composition Study 109 2347 9 335 0.51 (0.26-1.01) 34.1
Osteoporotic Fractures in Men Study (MrOS) 39 1411 4 147 0.92 (0.33-2.59) 18
EPIC-Norfolk Study 16 11,986 2 720 1.83 (0.42-8.05) 9.6
Invecchiare in Chianti Study 10 1066 1 33 2.93 (0.36-23.6) 5
Rotterdam Study 65 1611 7 107 1.38 (0.63-3.01) 27.9
Busselton Health Study 16 1907 1 89 0.94 (0.12-7.20) 5.3
Total (τ2 = 0.06) 255 20,328 24 1431 0.96 (0.59-1.55) 100
Forest plotStudy 
Euthyroidism Subclinical Hypothyroidism
HR (95% CI) Weight, %
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